CN102485261B - Medicine for treating diabetes and preparation method thereof - Google Patents
Medicine for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN102485261B CN102485261B CN201010571764.8A CN201010571764A CN102485261B CN 102485261 B CN102485261 B CN 102485261B CN 201010571764 A CN201010571764 A CN 201010571764A CN 102485261 B CN102485261 B CN 102485261B
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- dispersible tablet
- ginseng
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 35
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 239000009636 Huang Qi Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000010992 reflux Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 24
- 239000007919 dispersible tablet Substances 0.000 claims description 24
- 241000208340 Araliaceae Species 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 16
- 210000003038 endothelium Anatomy 0.000 claims description 15
- 239000008517 radix Trichosanthis Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 229920003081 Povidone K 30 Polymers 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 239000008188 pellet Substances 0.000 abstract description 2
- 238000000227 grinding Methods 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 235000014347 soups Nutrition 0.000 abstract 2
- 241000605447 Anemarrhena Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000007244 Zea mays Nutrition 0.000 abstract 1
- 229930191283 anemarrhena Natural products 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 229940089639 cornsilk Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 210000004317 gizzard Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 239000001231 zea mays silk Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 55
- 239000008103 glucose Substances 0.000 description 55
- 239000008280 blood Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 38
- 210000002700 urine Anatomy 0.000 description 27
- 235000005911 diet Nutrition 0.000 description 13
- 230000037213 diet Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 239000006187 pill Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating diabetes and specifically to a Chinese patent medicine prepared from Chinese herbal medicines and a preparation method thereof. The medicine is prepared from the following bulk drugs by weight: 130 to 180 g of ginseng, 425 to 475 g of radix astragali, 730 to 780 g of cortex lycii, 275 to 325 g of root of kudzu vine, 275 to 325 g of anemarrhena, 275 to 325 g of Chinese yam, 350 to 400 g of trichosanthes root, 220 to 270 g of Chinese magnoliavine, 125 to 175 g of chicken's gizzard membrane and 260 to 310 g of corn silk. The preparation method comprises the following steps: weighing the bulk drugs according to a weight ratio, carrying out micro grinding, ethanol reflux extraction, water decoction and filtration on the bulk drugs, merging soup, carrying out condensation, uniform mixing, drying and ultramicro grinding on the merged soup so as to obtain main drug submicron powder and uniformly mixing the submicron powder with accessories so as to prepare dispersing tablets or slow release pellets.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diabetes, the Chinese patent medicine that the Chinese herbal medicine of specifically take is prepared as raw material.The invention still further relates to the preparation method of this medicine.
Background technology
Diabetes be one group due to insulin secretion and (or) effect defect cause, take that chronic blood glucose increases the metabolic disease as feature.Various complication due to it have become that patient is disabled, the one of the main reasons of premature death.The death toll causing at developed country's diabetic complication is after cardiovascular and cerebrovascular disease, cancer, to be listed as the 3rd.Up to now, diabetes remain a kind of disease that is difficult to one-time cure, and except patient controls with diet and exercise therapy, oral antidiabetic drug is occupied very consequence in the treatment of diabetes, and approximately 70% diabetics needs the treatment of long-term taking antidiabetic drug.
Diabetics there will be metabolism of blood glucose and metabolism disorder of blood lipid mostly, and due to the glycolysis of liver, the approach such as the synthetic and raw fat effect of glycogen are difficult for starting, and are obstructed in blood glucose outlet.New oral hypoglycemic constantly goes on the market, and for clinical treatment provides condition, also to rational use of drug, brings certain difficulty.Reasonable selection orally-taken blood sugar reducing medicine, significant for prevention and minimizing adverse effect.Therefore, develop a kind of toxic and side effects little, convenient oral, the Chinese medicine novel form hypoglycemic medicine that bioavailability is high, very urgent, very important in order to treat the complication of the diabetes such as diabetes and pedopathy, nephropathy, oculopathy, encephalopathy, heart disease.
Summary of the invention
One of the object of the invention is to provide a kind ofly can treat the medicine of diabetes significantly, stably; Guarantee that this medicine also has definite, controlled therapeutical effect to treatment diabetes and complication thereof.
Two of the object of the invention is to provide a kind of novel form for the treatment of diabetes medicament--the preparation method of dispersible tablet, the preparation technology of this dosage form selects novel disintegrating agent and diluent to prepare and absorb Chinese medicine (rapid release) preparation fast, bioavailability is high with reference to the design philosophy of rapidly disintegrating formulation, and the Chinese medicine research of Zhe Jiangdui China and exploitation produce significant impact.
Three of the object of the invention is to provide a kind of novel form for the treatment of diabetes medicament--the preparation method of slow-release micro-pill, the preparation technology of this dosage form is simple, for raising Chinese Herbs, raising bioavailability, release, stablize, promote new drug development and promote the modernization of Chinese medicine to there is immeasurable effect, there is good scientific research and application prospect.
The object of the present invention is achieved like this, and medicine of the present invention is to be made by the crude drug of following weight proportion:
Radix Ginseng 130-180g, Radix Astragali 425-475g, Cortex Lycii 730-780g,
Radix Puerariae 275-325g, Rhizoma Anemarrhenae 275-325g, Rhizoma Dioscoreae 275-325g,
Radix Trichosanthis 350-400g, Fructus Schisandrae Chinensis 220-270g, Endothelium Corneum Gigeriae Galli 125-175g,
Stigma Maydis 260-310g.
1. the method for, the medicine of said ratio being made to dispersible tablet is: ginseng submicron powder is broken; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered, and medicinal liquid is standby; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, and each 1.5 hours, merge decoction liquor, filter; Merge with above-mentioned medicinal liquid, be concentrated into relative density 1.35-1.37(60 ℃) clear paste, add ginseng submicron powder, mix, dry, micronizing, obtain principal agent superfine powder, mix with calcium sulfate, with 10% PVP K30 aqueous solution, make binding agent, granulate, dry, add crospolyvinylpyrrolidone, tween 80, micropowder silica gel, mix, make dispersible tablet, obtain.
2. the preparation method of, the medicine of said ratio being made to slow-release micro-pill is: Radix Ginseng powder is broken into fine powder; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, each 1.5 hours, merge decoction liquor; Merge with said extracted liquid, be concentrated into relative density 1.35-1.37(60 ℃) clear paste, add Radix Ginseng fine powder, winner's ointment powder, adds microcrystalline Cellulose, mixes, and adds adhesive soft material processed, makes micropill, wraps slow release film-coat, obtains.
Dispersible tablet adjuvant is equipped with calcium sulfate 30-50%(filler), crospolyvinylpyrrolidone 4-8%(disintegrating agent), 10% PVP K30 aqueous solution 2-6%(adhesive), tween 80 0.2-0.6%(surfactant), micropowder silica gel 2-6%(lubricant); Micropill adjuvant is equipped with microcrystalline Cellulose 20%-40%.
Wherein the interpolation quantity of adjuvant be the weight of principal agent superfine powder/principal agent cream powder of obtaining be basis.
Described dispersible tablet, every heavy 0.6g, 12 of every plates, every box 2 plates; Instructions of taking: every day 3 times, each 2-4 sheet.
Described slow-release micro-pill, 0.2g*12 grain/0.125*24 grain; Instructions of taking: every day 3 times, each 4/8.
Medicine of the present invention has the following advantages and good effect:
1, medicine of the present invention can effectively reduce blood glucose, regulates the electrolyte disturbance of health, recovers function, improve complication, liver and kidney tonifying, slakes thirst and help produce saliva, for the treatment of non-insulin-dependent diabetes mellitus (type Ⅱdiabetes mellitus), be mainly manifested in and emphasize equilibrium between yin and yang, integrally-regulated, thus reach recovery pancreatic function, play dual regulation, both blood sugar lowering, can prevent hypoglycemia again.
2, herbal mixture dispersible tablet formulation of the present invention can significantly strengthen its blood sugar reducing function, and reduces its consumption and toxic and side effects, in treatment diabetes, can effectively reduce the generation of its complication.
3, herbal mixture sustained-release pellet preparation of the present invention, can be steady, lasting release medicine, and when improving bioavailability, slowly release more can alleviate toxic and side effects and the zest to human body.
clinical data
Physical data: this group patient is the 10 routine diabeticss that hospital receives treatment, without matched group.
Treatment group patient's 10 examples, wherein man, each 5 examples of female.Maximum 75 years old age, minimal ages 37 years old, 54.5 years old mean age, the elder of the course of disease 13 years, the shortest person half a year.
Diagnostic criteria: adopt blood sample, urine sample analyzer is measured, the diabetes diagnosis newest standards of formulating with reference to country: 1, have classical symptom, fasting glucose >=7.0 mmol/l or post-prandial glycemia >=11.1 mmol/l; 2, there is no classical symptom, only fasting glucose >=7.0 mmol/l or post-prandial glycemia >=11.1 mmol/l should repeat once again, still reach above value person, can be diagnosed as diabetes; 3, there is no classical symptom, only fasting glucose >=7.0 mmol/l or post-prandial glycemia >=11.1 mmol/l carbohydrate tolerance are tested 2 hours blood glucose >=11.1 mmol/l persons, can be diagnosed as diabetes.
Treatment standard: a kind of hypoglycemic medicine is oral, one month is a course for the treatment of, and check blood glucose and urine sugar level should decline, and continues to take rear blood glucose and urine sugar level and should reach the national arm's length standard of formulating.
Clinic control: euglycemia, the urine sugar level that after taking medicine, blood glucose and urine sugar level return to national regulation is decided to be effective, after taking medicine, blood glucose and urine sugar level decline and are decided to be improvement, after taking medicine the index of blood glucose and glucose in urine without change, be decided to be invalid.
The therapeutic outcome of this group clinical case: obvious effective rate 93%, takes a turn for the better 7%, clinical total effective rate 100%.
clinical case
Case 1 patient's Records of the Historian, man, 49 years old, live young road, Kuancheng District, Changchun, Jilin, ill 5 years, facial area and edema of pair of lower extremities, routine urianlysis: urine protein (++～+++) is simultaneously poor with diet, and complexion is not good enough, the dizzy symptom such as weak.Local doctor informs and should not use sulphanylureas and biguanide antidiabetic medicament again, in order to avoid make impaired renal function.Therefore start to take medicine of the present invention in August, 06, the two weeks of taking medicine, edema phenomenon disappears.Take medicine a course for the treatment of (one month), polydipsia, polyuria, the transference cure of eating more, body weight increases 5kg.Result of laboratory test: blood glucose 7.5 mmol/L, glucose in urine (+-).Continue to take medicine two months, result: blood glucose is down to 5.0 mmol/L, glucose in urine (-), drug withdrawal, keeps on a diet.
Case 2 patient Wang Nan, female, 55 years old, live near Ya Tai street, Changchun, Jilin, ill 11 years, routine urianlysis: urine protein (+++), three-many-one-little, simultaneously with retinal hemorrhage, the dizzy symptom such as weak.Start to take medicine of the present invention in February, 09, takes medicine 10 days, and amount of drinking water reduces, and voided volume reduces.Take medicine a course for the treatment of (one month), retinal hemorrhage phenomenon disappears.Result of laboratory test: blood glucose 7.0 mmol/L, glucose in urine (+-).Continue to take medicine two months, result: blood glucose is down to 5.2 mmol/L, glucose in urine (-), suspends drug withdrawal, diet control.
Case 3 patient Wang Shanshan, female, 42 years old, live near the Jilin University of Changchun, Jilin, in June, 2010, doctor was diagnosed as type Ⅱdiabetes mellitus, blood glucose: 6.2 mmol/L, glucose in urine: (+-), subjective symptoms: xerostomia, polydipsia, night frequent micturition, polyphagia, easily starve, do not take medicine always, by diet control, but blood glucose is still higher, and clinical symptoms loses.Within 2010, JIUYUE starts to take medicine of the present invention on 25th, serve on 20 days, and subjective symptoms all disappears, and through chemical examination blood glucose 5.6 mmol/L, glucose in urine (-), serve on after one month, by diet control, had reached clinical recovery.
Case 4 patient Li Qiangs, man, 69 years old, live Dehui City, Jilin Province, conscious polydipsia at the beginning of 2006, appetite increases, hunger, frequent micturition.In JIUYUE, 2006 inspection: blood glucose 9.3 mmol/L, glucose in urine (+-), through glucose tolerance test, be diagnosed as type Ⅱdiabetes mellitus.Diet control before this, clinical symptoms is without obvious change.On January 21st, 2009 starts to take medicine of the present invention, and after the course for the treatment of, subjective symptoms all disappears, through chemical examination blood glucose 6.0 mmol/L, glucose in urine (-), the clinical recovery from illness standard that reaches.
The high hypo of case 5 patient, man, 75 years old, lives Jilin, Jilin Province, suffer from diabetes 13 years, once took multiple Chinese and Western hypoglycemic medicine, it is unstable that some Western medicine are taken rear blood glucose, fluctuated, often occur hypoglycemia, informal dress is large with Western medicine side effect, has Drug resistance, takes some Chinese medicine hypoglycemic effects not good.Chemically examine blood glucose 12.3 mmol/L in February, 2000, glucose in urine (+++), takes 2 of the medicines of the present invention blood glucose course for the treatment of and is down to 5.8 mmol/L, and glucose in urine (-), reaches arm's length standard, and doctor's advice is strictly kept on a diet.
Case 6 patient Zhang Nan, female, 37 years old, live near Chongqing road, Changchun City, suffer from diabetes half a year, occurred before this serious xerostomia, happiness drink, frequent micturition, after take Chinese medicine decoction one month, cause stomachache, cut out Chinese medicine latter two month, chemical examination blood glucose reaches 8.5 mmol/L, and three-many-one-little symptom increases the weight of.Now take a course for the treatment of of medicine of the present invention, chemical examination blood glucose reaches normal level, three-many-one-little transference cure, and the after treatment in month that continues to take medicine, doctor's advice is careful in one's diet.
Case 7 patient's Liu Lilis, female, 56 years old, live Changchun City, suffer from diabetes medical history 7 years, 2004 ill, at that time assay: blood glucose 8.3 mmol/L, glucose in urine (++), take medicine two weeks of the present invention, blood glucose is down to 5.3 mmol/L, glucose in urine (-), again take two weeks and consolidate curative effect, reach criterion of cure.
Case 8 patient Nan Youhai, man, 59 years old, live near street, Silicon Valley, Changchun City, within 2009, suffer from inspection type Ⅱdiabetes mellitus, blood glucose 9.8 mmol/L, glucose in urine (++), merging neuralgia, body void is weak, skelalgia, starts to take medicine of the present invention after ill, takes continuously 2 courses for the treatment of, conscious various pain disappears, chemical examination blood glucose 5.8 mmol/L of hospital, glucose in urine (-), doctor advised drug withdrawal, dietary adjustments.
9 patients are fragrant the first month of autumn for case, female, 62 years old, live Changchun City, 95 years are ill, through doctor's result of laboratory test: and blood glucose 11.5 mmol/L, glucose in urine (++), take for many years Western medicine always, after take again Chinese medicine decoction two weeks, under the weather cutting out, after take 3 courses for the treatment of of medicine of the present invention, blood glucose is down to 6.5 mmol/L, after the course for the treatment of of continuing to take medicine, changes dietary adjustments into.
Case 10 patient Cai Yongjiu, man, 41 years old, live Jiutai City, Jilin Province, 2008 the year end assay, blood glucose 8.9 mmol/L, glucose in urine (+-), through glucose tolerance test, is diagnosed as type Ⅱdiabetes mellitus.Start to keep on a diet, do not take medicine, clinical symptoms increases the weight of, and again checks blood glucose 9.5 mmol/L, glucose in urine (++), start to take medicine of the present invention in June, 2009, and after the course for the treatment of, felling ailments oneself disappears, chemical examination blood glucose 5.5 mmol/L, glucose in urine (-), the clinical recovery from illness index that reaches, suggestion is kept on a diet, assisted movement.
The specific embodiment
embodiment 1
Weighting raw materials Radix Ginseng 130g in proportion, Radix Astragali 425g, Cortex Lycii 730g, Radix Puerariae 275g, Rhizoma Anemarrhenae 275g, Rhizoma Dioscoreae 275g, Radix Trichosanthis 350g, Fructus Schisandrae Chinensis 220g, Endothelium Corneum Gigeriae Galli 125g, Stigma Maydis 260g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 30%, crospolyvinylpyrrolidone 4%, 10% PVP K30 aqueous solution 2%, tween 80 0.2%, micropowder silica gel 2%.Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 20%.
Dispersible tablet processed: above-mentioned ginseng submicron powder is broken; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered, and medicinal liquid is standby; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, and each 1.5 hours, merge decoction liquor, filter; Merge with above-mentioned medicinal liquid, be concentrated into relative density 1.35(60 ℃) clear paste, add ginseng submicron powder, mix, dry, micronizing, principal agent superfine powder 225g, therefrom precision takes 100g and calcium sulfate 30g mixes, and with 10% PVP K30 aqueous solution 2g, makes binding agent, granulate, dry, add crospolyvinylpyrrolidone 4g, tween 80 0.2g, micropowder silica gel 2g, mix, make dispersible tablet, obtain.Above-mentioned tablet, every heavy 0.6g.
Slow-release micro-pill processed: above-mentioned Radix Ginseng powder is broken into fine powder; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, each 1.5 hours, merge decoction liquor; Merge with said extracted liquid, be concentrated into relative density 1.35(60 ℃) clear paste, add Radix Ginseng fine powder, the ointment powder 245g of winner, therefrom precision takes 100g and adds microcrystalline Cellulose 20g, mixes, and adds adhesive soft material processed, makes micropill, wraps slow release film-coat, obtains.Above-mentioned micropill, 0.2g*10 grain/0.125*20 grain.
embodiment 2
Weighting raw materials Radix Ginseng 140g in proportion, Radix Astragali 435g, Cortex Lycii 740g, Radix Puerariae 285g, Rhizoma Anemarrhenae 285g, Rhizoma Dioscoreae 285g, Radix Trichosanthis 360g, Fructus Schisandrae Chinensis 230g, Endothelium Corneum Gigeriae Galli 135g, Stigma Maydis 270g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 40%, crospolyvinylpyrrolidone 6%, 10% PVP K30 aqueous solution 4%, tween 80 0.4%, micropowder silica gel 4%; Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 30%.The method for making of its dispersible tablet and slow-release micro-pill is with embodiment 1.
embodiment 3
Weighting raw materials Radix Ginseng 150g in proportion, Radix Astragali 445g, Cortex Lycii 750g, Radix Puerariae 295g, Rhizoma Anemarrhenae 295g, Rhizoma Dioscoreae 295g, Radix Trichosanthis 370g, Fructus Schisandrae Chinensis 240g, Endothelium Corneum Gigeriae Galli 145g, Stigma Maydis 280g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 50%, crospolyvinylpyrrolidone 8%, 10% PVP K30 aqueous solution 6%, tween 80 0.6%, micropowder silica gel 6%; Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 40%.The method for making of its dispersible tablet and slow-release micro-pill is with embodiment 1.
embodiment 4
Weighting raw materials Radix Ginseng 160g in proportion, Radix Astragali 455g, Cortex Lycii 760g, Radix Puerariae 305g, Rhizoma Anemarrhenae 305g, Rhizoma Dioscoreae 305g, Radix Trichosanthis 380g, Fructus Schisandrae Chinensis 250g, Endothelium Corneum Gigeriae Galli 155g, Stigma Maydis 290g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 30%, crospolyvinylpyrrolidone 4%, 10% PVP K30 aqueous solution 2%, tween 80 0.2%, micropowder silica gel 2%.Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 20%.
Dispersible tablet processed: above-mentioned ginseng submicron powder is broken; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered, and medicinal liquid is standby; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, and each 1.5 hours, merge decoction liquor, filter; Merge with above-mentioned medicinal liquid, be concentrated into relative density 1.37(60 ℃) clear paste, add ginseng submicron powder, mix, dry, micronizing, obtain principal agent superfine powder, mix with calcium sulfate, with 10% PVP K30 aqueous solution, make binding agent, granulate, dry, add crospolyvinylpyrrolidone, tween 80, micropowder silica gel, mix, make dispersible tablet, obtain.Above-mentioned tablet, every heavy 0.6g.
Slow-release micro-pill processed: above-mentioned Radix Ginseng powder is broken into fine powder; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, each 1.5 hours, merge decoction liquor; Merge with said extracted liquid, be concentrated into relative density 1.37(60 ℃) clear paste, add Radix Ginseng fine powder, winner's ointment powder, adds microcrystalline Cellulose, mixes, and adds adhesive soft material processed, makes micropill, wraps slow release film-coat, obtains.Above-mentioned micropill, 0.2g*10 grain/0.125*20 grain.
embodiment 5
Weighting raw materials Radix Ginseng 170g in proportion, Radix Astragali 465g, Cortex Lycii 770g, Radix Puerariae 315g, Rhizoma Anemarrhenae 315g, Rhizoma Dioscoreae 315g, Radix Trichosanthis 390g, Fructus Schisandrae Chinensis 260g, Endothelium Corneum Gigeriae Galli 165g, Stigma Maydis 300g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 40%, crospolyvinylpyrrolidone 6%, 10% PVP K30 aqueous solution 4%, tween 80 0.4%, micropowder silica gel 4%; Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 30%.The method for making of its dispersible tablet and slow-release micro-pill is with embodiment 4.
embodiment 6
Weighting raw materials Radix Ginseng 180g in proportion, Radix Astragali 475g, Cortex Lycii 780g, Radix Puerariae 325g, Rhizoma Anemarrhenae 325g, Rhizoma Dioscoreae 325g, Radix Trichosanthis 400g, Fructus Schisandrae Chinensis 270g, Endothelium Corneum Gigeriae Galli 175g, Stigma Maydis 310g.
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 50%, crospolyvinylpyrrolidone 8%, 10% PVP K30 aqueous solution 6%, tween 80 0.6%, micropowder silica gel 6%; Micropill adjuvant adds quantity take and obtain principal agent cream grain weight amount as basis, adds microcrystalline Cellulose 40%.The method for making of its dispersible tablet and slow-release micro-pill is with embodiment 4.
Claims (1)
1. a dispersible tablet for the treatment of diabetes, is characterized in that: weighting raw materials Radix Ginseng 130g in proportion, Radix Astragali 425g, Cortex Lycii 730g, Radix Puerariae 275g, Rhizoma Anemarrhenae 275g, Rhizoma Dioscoreae 275g, Radix Trichosanthis 350g, Fructus Schisandrae Chinensis 220g, Endothelium Corneum Gigeriae Galli 125g, Stigma Maydis 260g;
Dispersible tablet adjuvant adds quantity take and obtain principal agent superfine powder weight as basis, adds calcium sulfate 30%, crospolyvinylpyrrolidone 4%, 10% PVP K30 aqueous solution 2%, tween 80 0.2%, micropowder silica gel 2%;
Dispersible tablet processed: above-mentioned ginseng submicron powder is broken; Radix Puerariae, Fructus Schisandrae Chinensis add 75% alcohol reflux three times, and each 1.5 hours, merge extractive liquid,, filtered, and medicinal liquid is standby; The Radix Astragali, Cortex Lycii, the Rhizoma Anemarrhenae, Rhizoma Dioscoreae, Radix Trichosanthis, Endothelium Corneum Gigeriae Galli and Stigma Maydis decoct with water three times, and each 1.5 hours, merge decoction liquor, filter; Merge with above-mentioned medicinal liquid, 60 ℃ of clear paste that are concentrated into relative density 1.35, add ginseng submicron powder, mix, dry, micronizing, obtain principal agent superfine powder 225g, therefrom precision takes 100g and calcium sulfate 30g mixes, and 10% PVP K30 aqueous solution 2g makes binding agent, granulates, dry, add crospolyvinylpyrrolidone 4g, tween 80 0.2g, micropowder silica gel 2g, mix, make dispersible tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010571764.8A CN102485261B (en) | 2010-12-03 | 2010-12-03 | Medicine for treating diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010571764.8A CN102485261B (en) | 2010-12-03 | 2010-12-03 | Medicine for treating diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102485261A CN102485261A (en) | 2012-06-06 |
| CN102485261B true CN102485261B (en) | 2014-10-29 |
Family
ID=46150856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010571764.8A Active CN102485261B (en) | 2010-12-03 | 2010-12-03 | Medicine for treating diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102485261B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535467A (en) * | 2016-01-27 | 2016-05-04 | 陈学义 | Traditional Chinese medicine watered pills for treating diabetes |
| CN105998854A (en) * | 2016-07-24 | 2016-10-12 | 刘咏梅 | Medicine for treating diabetic nephropathy and preparation method |
| CN108498734A (en) * | 2018-07-05 | 2018-09-07 | 程庸堂 | A kind of Chinese prescription for treating diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940349A (en) * | 2010-08-18 | 2011-01-12 | 齐齐哈尔医学院 | Corn stigma mineral water and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1159051C (en) * | 2002-03-28 | 2004-07-28 | 葛强 | Hypoglycemic granule of ten ingredients and its prepn |
-
2010
- 2010-12-03 CN CN201010571764.8A patent/CN102485261B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940349A (en) * | 2010-08-18 | 2011-01-12 | 齐齐哈尔医学院 | Corn stigma mineral water and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102485261A (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101164585B (en) | Medicine for curing gout and its preparing method | |
| CN102343023B (en) | Medicinal composition and preparation method and application thereof | |
| CN101757540A (en) | Traditional Chinese medicine composition for treating nephrotic syndrome and preparation method thereof | |
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| CN100586462C (en) | Wuji Baifeng granule, tablet or capsule and preparation method thereof | |
| CN102240318A (en) | Traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN102485261B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN101690789B (en) | Chinese medicinal preparation for treating diabetes | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN101744850A (en) | Preparation and application of total flavone extracted from plants, as well as pharmaceutical preparations thereof | |
| CN101513492A (en) | Chinese medicament for treating diabetes | |
| CN102018852B (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN102631595A (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN102366497B (en) | Medicinal compound preparation for treating diabetes and preparation method of medicinal compound preparation | |
| CN105055855A (en) | Traditional Chinese medicine composition having sleep improvement and immunity boost effects as well as preparation method and application of traditional Chinese medicine composition | |
| CN103007159B (en) | Chinese medicinal preparation for correcting pancreas islet function | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN102935144A (en) | Drug for treating climacteric syndrome and preparation process of drug | |
| CN101829272B (en) | Traditional Chinese medicine composition for treating diabetes mellitus and preparation method thereof | |
| CN105194301A (en) | Traditional Chinese medicine preparation for treating chronic cardiac failure | |
| CN101869666B (en) | Composition for nourishing kidney, tonifying energy, nourishing brain and allaying excitement and preparation method | |
| CN101066294B (en) | Chinese medicine prepn for invigorating kidney to reduce urination and its prepn | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN102552378A (en) | Lucerne and application of lucerne extract in preparing medicament for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 136504 in Siping City of Jilin province Ji Chun Lu No. 1 Applicant after: Jilin Jichun Pharmaceutical Co., Ltd. Address before: 136000 Siping City of Jilin province Hafo village Jichun pharmaceutical Applicant before: Jilin Jichun Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |